Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Non Operating Income (2019 - 2025)

BridgeBio Pharma's Non Operating Income history spans 7 years, with the latest figure at -$240.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 497.71% year-over-year to -$240.3 million; the TTM value through Dec 2025 reached -$209.1 million, down 511.77%, while the annual FY2025 figure was -$209.1 million, 511.77% down from the prior year.
  • Non Operating Income for Q4 2025 was -$240.3 million at BridgeBio Pharma, down from $16.5 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $100.0 million in Q2 2024 and bottomed at -$240.3 million in Q4 2025.
  • The 5-year median for Non Operating Income is $886500.0 (2021), against an average of -$7.2 million.
  • The largest YoY upside for Non Operating Income was 3059.02% in 2022 against a maximum downside of 8967.98% in 2022.
  • A 5-year view of Non Operating Income shows it stood at $37.6 million in 2021, then tumbled by 87.88% to $4.6 million in 2022, then soared by 377.59% to $21.8 million in 2023, then plummeted by 284.63% to -$40.2 million in 2024, then tumbled by 497.71% to -$240.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Non Operating Income are -$240.3 million (Q4 2025), $16.5 million (Q3 2025), and $6.5 million (Q2 2025).